As regulator prepares to approve Lenacapavir in the US, campaigners are urging the manufacturer, Gilead, to make it ‘available and affordable for all who need it’
This take generally comes from looking at the profits of successful drug X, while being unaware of (or ignoring) all of the drugs that have millions upon millions put into their R&D, that never result in anything that can go to market.
Overall profits will seem much higher than they actually are if you leave out that very-relevant data.
This take generally comes from looking at the profits of successful drug X, while being unaware of (or ignoring) all of the drugs that have millions upon millions put into their R&D, that never result in anything that can go to market.
Overall profits will seem much higher than they actually are if you leave out that very-relevant data.